01/09/2006
The Board of ReGen Therapeutics Plc (‘ReGen’) today announces that an Extraordinary General Meeting (‘EGM’) of the Company will be convened for 11.00 a.m. at the offices of Wilmer Cutler Pickering Hale and Dorr LLP, Alder Castle, 10 Noble Street, London EC2V 7QJ on 26 September 2006.
The Board announced on 21 July 2006 that the Company had raised gross funds of £1,110,000 through a placing of 111,000,000 new Ordinary Shares. In this announcement, ReGen mentioned that depending upon the actual timing of anticipated revenues from the commercialisation of Colostrinin(TM), the achievement of development milestones and whether other commercial opportunities present themselves, it may be necessary to raise additional amounts of capital in the future. Accordingly, the Board is seeking to renew Shareholder authority to be able to issue shares and/or other securities of the Company to facilitate future fundraisings (if required) and/or acquisitions of complementary businesses.
Further information on the proposed resolutions is set out in a circular containing the notice of EGM (the ‘Circular’) which was posted to shareholders of ReGen today.
Copies of the Circular will be available, for collection only, free of charge to the public, from ReGen, Suite 406, Langham House, 29-30 Margaret Street, London W1W 8SA during normal office hours on any day (Saturdays, Sundays excepted) from today until 25 September 2006.
For further information please contact:
Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile: 07785 297111